Novo Nordisk A/S (NYSE:NVO) Shares Sold by Trillium Asset Management LLC

Trillium Asset Management LLC trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 14.1% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 199,435 shares of the company’s stock after selling 32,731 shares during the period. Trillium Asset Management LLC’s holdings in Novo Nordisk A/S were worth $13,849,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BIP Wealth LLC grew its holdings in Novo Nordisk A/S by 3.9% in the 4th quarter. BIP Wealth LLC now owns 3,642 shares of the company’s stock worth $313,000 after buying an additional 138 shares in the last quarter. Xponance Inc. boosted its position in Novo Nordisk A/S by 5.0% during the 1st quarter. Xponance Inc. now owns 3,314 shares of the company’s stock worth $230,000 after acquiring an additional 158 shares during the period. Foster Dykema Cabot & Partners LLC grew its stake in shares of Novo Nordisk A/S by 3.8% in the first quarter. Foster Dykema Cabot & Partners LLC now owns 4,526 shares of the company’s stock worth $319,000 after purchasing an additional 166 shares in the last quarter. 180 Wealth Advisors LLC grew its stake in shares of Novo Nordisk A/S by 3.6% in the first quarter. 180 Wealth Advisors LLC now owns 5,014 shares of the company’s stock worth $348,000 after purchasing an additional 173 shares in the last quarter. Finally, LRI Investments LLC increased its holdings in shares of Novo Nordisk A/S by 1.4% during the fourth quarter. LRI Investments LLC now owns 13,060 shares of the company’s stock valued at $1,123,000 after purchasing an additional 176 shares during the period. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Barclays reaffirmed an “equal weight” rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Guggenheim cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. UBS Group lowered shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 5th. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Finally, BMO Capital Markets reissued a “market perform” rating and issued a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $93.67.

Novo Nordisk A/S Stock Down 2.3%

Shares of Novo Nordisk A/S stock opened at $49.88 on Tuesday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $139.74. The firm has a market capitalization of $222.73 billion, a PE ratio of 13.70, a price-to-earnings-growth ratio of 1.75 and a beta of 0.63. The stock’s fifty day moving average is $66.68 and its 200-day moving average is $71.20.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The company had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th will be paid a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date of this dividend is Monday, August 18th. Novo Nordisk A/S’s payout ratio is 45.05%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.